The Dark side of Hypomania

The Dark Side of Hypomania

While working on the American Psychiatric Association’s latest DSM version of bipolar disorder (IV-TR), Trisha Suppes MD, PhD of the University of Texas Medical Center in Dallas carefully read its criteria for hypomania, and had an epiphany. “I said, wait,” she told a UCLA grand rounds lecture in April 2003, “where are all those patients of mine who are hypomanic and say they don’t feel good?”

The DSM defines hypomania as “a distinct period of persistently elevated, expansive, or irritable mood,” but the overwhelmingly standard misconception is one of unadulterated exuberance. Ask your typical patient about hypomania and he or she will fondly recall those life-of-the-party and unbelievably productive moments and reply, “if only I could put it in a bottle and sell it.” And a psychiatrist off the record may add, with a hint of envy, “if only I could buy it.”

But what about road rage and other destructive behaviors? The DSM recognizes “mixed” states in mania where highs and lows simultaneously run riot in the brain, but nowhere does it acknowledge a parallel phenomenon in hypomania. Does mixed hypomania exist and how common is it? Dr Suppes decided to find out. The results of her seven-year investigation appear in the October Archives of General Psychiatry.

Drawing from patients in seven clinics associated with the Stanley Foundation Bipolar Treatment Network, Dr Suppes and her colleagues gathered prospective data on 908 bipolar patients (most by far with bipolar I). Of 14,328 visits by patients, 1,044 involved hypomania. Examinations of the patients in this state found that the majority (57 percent) “met criteria for mixed hypomania.”

By “mixed hypomania,” patients must have met the researchers’ threshold for at least mild hypomania (corresponding to a YMRS score of 12 or greater) combined with at least mild depression (corresponding to an IDS-C score of 15 or greater).

Patients with bipolar I were far more likely to experience hypomania than those with bipolar II, though the likelihood of mixed states within each diagnosis remained about the same. Women were significantly more likely to experience mixed states than men (72 percent vs 42 percent). Women in the study with no hypomania had a 41 percent probability of experiencing depression. This increased to 66 percent with mild hypomania and 81 percent with moderate hypomania, then dipped back to 67 percent with severe hypomania.

Although there was no association between hypomanic and depressive symptoms in men, the authors of the study concluded that “men are far more likely to be irritable and agitated when hypomanic.”

Dr Suppes and her colleagues observe that one reason bipolar II patients are misdiagnosed with depression is “the expectation that hypomania is predominantly euphoric.” Patients tend not to report mixed episodes and psychiatrists often fail to ask the right questions. The result, they say, may lead to inappropriate treatments, such as antidepressant monotherapy which may induce increased cycling.

Read on …

Dysphoric Hypomania

The unofficial title of Dr Mood Spectrum belongs to Hagop Akiskal MD of the University of California, San Diego. Entering “mixed” to his name on PubMed turns up 47 published articles. His latest one, in the October Bipolar Disorders, reinforces Dr Suppes’ study and adds new insights.

From a sample of 320 bipolar II patients, Dr Akiskal and frequent collaborator, Franco Benazzi MD of the Hecker Outpatient Center (Ravenna) focused on 45 who presented with both hypomania and major depression. This meant that euphoric mood was absent. Instead, hypomania was based on the often overlooked DSM criteria for irritable mood plus four hypomanic symptoms.

The authors define this hypomania-major depression double-whammy as “dysphoric hypomania,” which roughly corresponds to Dr Suppes “mixed hypomania,” but sets a higher threshold involving more severely ill patients.

Comparing these patients to the “pure” bipolar II patients in the study found that those with dysphoric hypomania experienced more agitated depressions by a wide margin (86.6 percent vs 5.8 percent) and evidenced more atypical features (such as mood reactivity). Hypomanic symptoms included racing thoughts, distractibility, being more talkative, excessive risky activities, and increased goal-directed activity. Women were more likely to experience dysphoric hypomania than men.

Clearly, these individuals require urgent attention. Unfortunately, say the authors of the study, this “dark facet” of hypomania “is likely to be relegated to the domain of erratic personality disorders.”

Based on their previous work and the work of others, the authors propose a continuum of mixed states that includes:

DSM-IV mixed state (dysphoric mania).
Mixed mania (mania with a few depressive symptoms).
Dysphoric hypomania (hypomanic episode plus full major depression).
Depressive mixed state (major depressive episode plus a few hypomanic behaviors. A landmark 2001 study by the same authors found at least two hypomanic symptoms in 73.1 percent of bipolar II depressions and 42.1 percent of unipolar major depressions. Three or more hypomanic symptoms were found in 46.3 percent of bipolar depressions and 7.8 percent of unipolar depressions.).
Agitated depression.
Think road rage, tall, venti, and grande, potentially dangerous in any brew. How safe are you?

Posted in News & updates | Leave a comment

Treatment of A Typical Depression with cognitive Therapy

Abstract

BACKGROUND:

Patients with atypical depression are more likely to respond to monoamine oxidase inhibitors than to tricyclic antidepressants. They are frequently offered psychotherapy in the absence of controlled tests. There are no prospective, randomized, controlled trials, to our knowledge, of psychotherapy for atypical depression or of cognitive therapy compared with a monoamine oxidase inhibitor. Since there is only 1 placebo-controlled trial of cognitive therapy, this trial fills a gap in the literature on psychotherapy for depression.

METHODS:

Outpatients with DSM-III-R major depressive disorder and atypical features (N = 108) were treated in a 10-week, double-blind, randomized, controlled trial comparing acute-phase cognitive therapy or clinical management plus either phenelzine sulfate or placebo. Atypical features were defined as reactive mood plus at least 2 additional symptoms: hypersomnia, hyperphagia, leaden paralysis, or lifetime sensitivity to rejection.

RESULTS:

With the use of an intention-to-treat strategy, the response rates (21-item Hamilton Rating Scale for Depression score, < or =9) were significantly greater after cognitive therapy (58%) and phenelzine (58%) than after pill placebo (28%). Phenelzine and cognitive therapy also reduced symptoms significantly more than placebo according to contrasts after a repeated-measures analysis of covariance and random regression with the use of the blind evaluator's final Hamilton Rating Scale for Depression score. The scores between cognitive therapy and phenelzine did not differ significantly. Supplemental analyses of other symptom severity measures confirm the finding.

CONCLUSIONS:

Cognitive therapy may offer an effective alternative to standard acute-phase treatment with a monoamine oxidase inhibitor for outpatients with major depressive disorder and atypical features

Posted in News & updates | Leave a comment

How common is A Typical Depression

In addition to the core symptoms of depression, atypical depression is defined by the ability to feel better temporarily in response to a positive life event, plus any two of the following criteria: excessive sleep, overeating, a feeling of heaviness in the limbs and a sensitivity to rejection.

Patients with atypical depression tend to have an earlier age of onset than those with other subtypes (it often first appears in the teenage years). These patients are also likely to have a history of social phobia, avoidant personalities and a history of body dysmorphic disorder.1

How Common Is Atypical Depression?

Despite the name, atypical depression is actually the most common subtype, according to Dr. Andrew A. Nierenberg, associate director of the depression clinical and research program at Massachusetts General Hospital, Boston. In a 1998 study, he and his associates found that 42% of participants had atypical depression, 12% had melancholic depression, 14% had both depression subtypes, and the rest had neither. “It’s more common than we all think. There’s no doubt we underrecognize it,”said Dr. Nierenberg.2

Making a correct diagnosis of this subtype is critical in providing the patient with effective treatment. Although SSRIs and other newer medications are often the first line choice for depression treatment due to their favorable side-effect profiles, very little is yet known about how well these work for the patient with atypical depression. What is known is that patients respond well to MAOIs, but not to tricyclics. Data on newer medications is sparse and inconclusive.3 How many patients out there may be suffering through drug trial after drug trial simply because their physician does not know which medication best treats atypical depressions or does not recognize this distinct subtype?

How Is Atypical Depression Treated?

Current data suggests that those with atypical depression will respond better to MAOIs (monoamine oxidase inhibitors) like phenelzine than they will to imipramine (a tricyclic). Dietary restrictions and side-effects remain a problem. At the present time, research is concentrating on finding newer medications with better side-effect profiles to which these patients will also get a good response.4

Although more research is needed, it seems that patients may also obtain an adequate response with the SSRIs, but not all studies seem to back up this assertion. In one study, the SSRI Prozac was found to have a response only equal to imipramine, a tricyclic whose comparative response to phenelzine is well-known.5

Interestingly, however, drug treatment may not be necessary at all. A study conducted in 1999 found that patients receiving cognitive behavioral therapy responded just as well as patients receiving the MAOI phenelzine. 58% of patients in both groups responded, in comparison to only 28% of patients in the placebo group.6

Implications for the Patient

It is important to see a psychiatrist rather than your primary care physician for treatment. Not all depressions are alike nor do they respond to the same medications. A physician in general practice is not likely to have the experience necessary to differentiate between subtypes of depression or to know which treatment choices are more likely to work. A patient may suffer unnecessarily as his doctor tries all the wrong medications. Given the very nature of depression, this only complicates the patient’s already depressed feelings. If the patient is forced by insurance or financial circumstances to see a primary care physician for their treatment, they must do the leg work to make up the deficit in their physician’s knowledge. This is not as it should be, certainly, but until there is a radical change in our healthcare systems, it is necessary. The educated healthcare consumer who takes an active role in his or her treatment is less likely to slip through the diagnostic cracks.

Posted in News & updates | Leave a comment

Bipolar #1 and Bipolar #2 Substance Abuse Disorders

Abstract

OBJECTIVE:

To evaluate the prevalence of substance abuse dependence and/or alcohol abuse dependence among subjects with bipolar I versus bipolar II disorder in a voluntary registry.

METHOD:

One hundred randomly selected registrants in a voluntary case registry for bipolar disorder were interviewed, using the Structured Clinical Interview for DSM-IV Axis I Disorders, to validate the diagnosis of this registry. Corroborative information was obtained from medical records, family members and the treating psychiatrist. Eighty-nine adults (18-65 years) met criteria for bipolar disorder (bipolar I = 71, bipolar II = 18) and were included in this analysis.

RESULTS:

Forty-one (57.8%) subjects with bipolar I disorder abused, or were dependent on one or more substances or alcohol, 28.2% abused, or were dependent on, two substances or alcohol, and 11.3% abused or were dependent on three or more substances or alcohol. Nearly 39% of bipolar II subjects abused or were dependent on one or more substances, nearly 17% were dependent on two or more substances or alcohol, and 11% were dependent on three or more substances or alcohol. Alcohol was the most commonly abused drug among either bipolar I or II subjects.

CONCLUSIONS:

Consistent with other epidemiologic and hospital population studies, this voluntary bipolar disorder registry suggests a high prevalence of comorbidity with alcohol and/or substance abuse dependence. Bipolar I subjects appear to have higher rates of these comorbid conditions than bipolar II subjects; however, as the number of bipolar II subjects was rather small, this suggestion needs confirmation.

Posted in News & updates | Leave a comment

Part # 3 Mood Stablizers and Novel Anti Pshychotics in the treatment of Borderline Personality Disorder

Conclusions

Recent investigations of mood stabilizers in the treatment of BPD are promising and suggest that these drugs can be useful in clinical practice, particularly for controlling affective instability and impulsive aggression. However, further studies are needed to confirm the initial results and to ascertain whether some novel antipsychotics can be used for their mood-stabilizing effects in patients with BPD.

Future investigations should focus on a list of relevant topics: pilot studies of new drugs; controlled trials of drugs already tested in open case series; comparisons of new anticonvulsant agents with better-known mood stabilizers, such as lithium or valproate; head-to-head comparisons of novel and traditional antipsychotics to verify which differences in clinical effects and adverse events specifically occur in patients with BPD; maintenance studies to assess persistence of therapeutic effects in longlasting disorders such as BPD; add-on trials of mood stabilizers and novel antipsychotics in samples of patients with BPD who do not respond to firstline therapy with serotonergic antidepressants; and the relationship of clinical subtypes of patients with BPD (eg, affective labile, self-injurious, psychotoform) with response to drug treatment.

Dr Bellino is assistant professor of psychiatry, Dr Paradiso is a resident in psychiatry, and Dr Bogetto is professor of psychiatry and chairman in the department of neuroscience at the University of Turin in Italy.

Drs Bellino, Paradiso, and Bogetto report that they have no conflicts of interest with the subject matter of this article.

Drugs Mentioned in This Article

Carbamazepine (Carbatrol, Tegretol, others)
Clonazepam (Klonopin, Rivotril)
Clozapine (Clozaril)
Divalproex (Epival, Depakote)
Fluoxetine (Prozac)
Lamotrigine (Lamictal)
Lithium (Eskalith)
Olanzapine (Zyprexa)
Oxcarbazepine (Trileptal)
Phenytoin (Dilantin)
Quetiapine (Seroquel)
Risperidone (Risperdal)
Tranylcypromine (Parnate)
Trifluoperazine (Stelazine)
Valproate/valproic acid (Depakote, others)
– See more at: http://www.psychiatrictimes.com/articles/mood-stabilizers-and-novel-antipsychotics-treatment-borderline-personality-disorder/page/0/3#sthash.fn2Sab7Y.dpuf

Posted in News & updates | Leave a comment

Part #2 Mood Stablizers and Novel Anti Psychotics in the Treatment of Borderline Personality Disorder

Part #2

Oxcarbazepine

Oxcarbazepine is another anticonvulsant structurally related to carbamazepine, with the same mechanism of action of blocking voltage-gated sodium channels, but it is less likely to induce cytochrome P-450 and drug interactions.19 A series of studies indicated the efficacy of oxcarbazepine in the treatment of several psychiatric disorders, such as bipolar disorder, substance abuse, resistant psychosis, and schizoaffective disorder. 27-40 However, as in the case of carbamazepine, oxcarbazepine has been approved by the FDA for treating only seizure disorder.

Our research group recently performed a 12-week pilot study of oxcarbazepine in 13 outpatients with BPD.41 A statistically significant improvement was observed in global psychopathology; anxiety; interpersonal relationships; and BPD core features, including impulsivity, affective instability, and outbursts of anger.

Divalproex sodium and valproate

Among mood stabilizers, divalproex sodium has been extensively studied in patients with BPD. Its mechanism of action consists of facilitating transmission of y-aminobutyric acid.42 Wilcox43,44 was the first to suggest the role of divalproex in reducing agitation in patients with BPD. In 1994, Wilcox43 tested the efficacy of valproate in a group of patients with psychomotor agitation caused by various underlying psychiatric conditions. The decrease in agitation after treatment was particularly evident in patients with bipolar disorder or BPD. These data were replicated in a subsequent study by Wilcox44 concerning the treatment of BPD with divalproex sodium.

An 8-week open-label trial of valproate (daily dose titrated to reach blood levels of 50 to 100 μg/mL) in 11 patients with BPD by Stein and colleagues45 provided further data on this agent. Of the 8 who completed the study, half were responders on clinician-rated measures of overall psychopathology, mood, anxiety, anger, impulsivity, and rejection sensitivity.

Kavoussi and Coccaro46 administered valproate (up to 2000 mg/d) to 10 patients with several Axis II diagnoses who had failed to respond to an SSRI (2 patients met criteria for BPD). After 8 weeks of treatment, irritability and impulsive aggressiveness were significantly reduced.

Subsequently, 3 placebo-controlled trials were published. Hollander and colleagues47 performed a 10-week double-blind study of valproate (plasma level of 80 μg/mL) in 16 patients with BPD and found a marked improvement in global symptomatology; social functioning; and BPD features, such as depressive symptoms, aggressiveness, irritability, and suicidal ideation or behavior. However, a high dropout rate precluded finding significant differences between treatment groups.

More recently, the same study group confirmed the efficacy of valproate (mean daily dose, 1325 mg) on impulsive aggression of 52 outpatients with BPD in a 12-week double-blind trial.48 Frankenburg and Zanarini49 included 30 women with BPD and comorbid bipolar II disorder in a 6-month controlled study and showed that valproate (plasma level of 50-100 μg/mL) had significant effects on interpersonal sensitivity, anger, hostility, and aggressiveness.

Lamotrigine

The anticonvulsant lamotrigine has been considered in recent years for treating depressive episodes of bipolar disorder and preventing recurrences. This drug inhibits neuronal excitability and modifies synaptic plasticity by inhibiting voltage-activated sodium channels. Indirectly, these effects would be expected to regulate aberrant intracellular and intercellular signalling in critical regions of the limbic forebrain.50

The use of lamotrigine for treating BPD was initially reported by Pinto and Akiskal51 in a 1-year open-label trial focused on 8 outpatients. Their results showed that 40% reported a significant improvement in global functioning, sexual impulsiveness, substance abuse, and suicidal behavior. A review by Green52 of patients with mood disorders suggests the efficacy of this agent in also treating mood instability of BPD.

More recently, Preston and colleagues53 investigated the frequency of comorbid BPD in 35 patients with bipolar disorder who had previously participated in 2 open-label trials with lamotrigine, in order to evaluate the effects of this drug on BPD dimensions. BPD was retrospectively diagnosed in 40% of the patients. Results of the study showed the efficacy of lamotrigine on all BPD traits, with a marked improvement in impulsivity and mood instability.

In 2005, Tritt and colleagues54 compared the efficacy of lamotrigine and placebo in the treatment of aggression in 24 women meeting the criteria for BPD. Highly significant improvements in anger were observed after 8 weeks in patients treated with lamotrigine.

Novel antipsychotics as mood stabilizers in BPD

Second-generation antipsychotics antagonize both dopamine and serotonin- 2 (5-HT2) receptors. Because dopamine receptor blockade has been associated with antimanic properties and 5-HT2 antagonism with antidepressant effects, it has been postulated that novel antipsychotics may be effective in the treatment and prevention of bipolar mania and depression.55 These hypotheses have been substantiated by a number of studies.5,56-60

The mood-stabilizing properties of second-generation antipsychotics have also been considered for treatment of BPD-related symptoms (Table 2). Although this indication has not yet been approved by the FDA, these agents are indicated by BPD treatment guidelines both for their antipsychotic effects on cognitive-perceptual disturbances and for their mood stabilizing action on affective instability, anger, and impulsive aggression.4

Clozapine was found to be efficacious on overall symptomatology, aggressiveness, and severe psychotic symptoms related to BPD.61-65 However, patients with BPD treated with clozapine frequently had Axis I comorbidities and had been refractory to previous treatments. These patients did not have pure BPD and they had already been treated unsuccessfully with other drugs.

To date, studies on risperidone in BPD are sparse and derive from some case reports and an open-label trial.66-69 In their 8-week open-label trial of risperidone (3.3 mg/d) in 15 outpatients with BPD, Rocca and colleagues69 outlined the efficacy of this agent on aggressive behavior, affective instability, and global psychopathology.

More extensive data suggesting mood stabilizing properties have been reported for olanzapine and quetiapine. Olanzapine is a thienobenzodiazepine with a high affinity for dopamine (D2 through D4) and serotonin receptors (5-HT2A), and a lower affinity for histamine (H1), muscarinic (M1 through M5), and α-adrenergic (α1) receptors. Antagonism at D2 through D4 and 5-HT2A receptors is supposed to be the basis for its therapeutic efficacy, while antagonism at H1, M1-M5, and α1 receptors is probably responsible for adverse effects.70

Schulz and colleagues71 performed the first open-label study of olanzapine in a sample of 9 outpatients with BPD who had comorbid dysthymia. After 8 weeks of treatment, patients reported a significant improvement in impulsivity, hostility, global psychopathology, and global functioning.

Since then, the findings from several controlled trials have been published. A 6-month double-blind, placebo-controlled trial of olanzapine (mean dose, 5.33 mg/d ± 3.43) in 28 women with BPD was undertaken by Zanarini and Frankenburg,72 who pointed out the efficacy of this agent on anxiety, paranoid ideation, and interpersonal sensitivity. Bogenschutz and Nurnberg73 recently reported similar findings in a 12-week double-blind, placebo-controlled trial of olanzapine (5 to 10 mg/d) in 40 outpatients with BPD. A significant improvement in borderline psychopathology and anger was found after the fourth week of treatment.

Zanarini and colleagues74 compared the efficacy of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination (OFC) in the treatment of 45 women meeting criteria for BPD. In their 8-week randomized double-blind study, the investigators found that all 3 treatment options significantly ameliorated chronic dysphoria and impulsive aggression. However, olanzapine monotherapy and OFC were found to be superior to fluoxetine monotherapy in treating both features of borderline psychopathology.

Soler and colleagues75 recently compared the efficacy of olanzapine and placebo in a combined treatment with dialectical behavioral therapy. In their 12-week double-blind study of a group of 60 outpatients with BPD, they found that olanzapine (mean dose, 8.83 mg/d) led to a significant reduction of impulsive- aggressive behavior, depression, and anxiety.

Quetiapine is a dibenzothiazepine characterized by low affinity for and rapid dissociation from postsynaptic D2 receptors, which reduces the incidence of adverse events, such as extrapyramidal symptoms, prolactin elevation, and weight gain.76-79 Hilger and colleagues80 described the impact of this agent (400 to 800 mg/d) on 2 women with BPD with severe episodes of self-mutilation and found positive effects on impulsive behavior and overall functioning.

A few pilot studies on quetiapine in BPD treatment have appeared in recent years. Adityanjee and Schulz81 evaluated the efficacy of quetiapine (25 to 300 mg/d) in 10 patients who completed an 8-week open-label trial. Results suggested a significant improvement in overall symptomatology, hostility, impulsivity, and functioning. Villeneuve and Lemelin82 recently replicated these findings. They investigated the effects of quetiapine (175 to 400 mg/d for 12 weeks) in a group of 23 outpatients and found a significant improvement in impulsivity, hostility, depression, anxiety, and social functioning.

Our group83 performed a 12-week pilot study on the efficacy of quetiapine (mean dose, 309 mg/d 83) for the treatment of BPD in 14 patients. Our results were mostly concordant with previous findings and confirmed the improvement of global symptomatology, impulsivity, outbursts of anger, anxiety, and social functioning.

Table 2

Clinical trials of some novel antipsychotics in the
treatment of borderline personality disorder

Agent Study
Design Number of

Patients Treatment
Duration Results

Risperidone
Rocca69 Open-label 15 8 weeks Decreased global symptomatology, aggression/mood instability

Olanzapine
Schulz71 Open-label 9 8 weeks Decreased global symptoms, impulsive aggression

Zanarini72 Double-blind
vs placebo 28 6 months Decreased anxiety/paranoid ideation, interpersonal sensitivity

Bogenschutz73 Double-blind vs placebo 40 12 weeks Decreased global symptomatology, anger

Zanarini74 Double-blind vs F vs 0 + F 45 8 weeks Decreased impulsive aggression, chronic dysphoria (O = O + F > F)

Soler75 Double-blind DBT + O vs DBT + placebo 60 12 weeks Decreased impulsive aggression, depression/anxiety

Quetiapine
Hilger80 Case report 2 NA Decreased impulsivity, improved global functioning

Adityanjee81 Open-label 10 8 weeks Decreased overall symptomatology, hostility/impulsivity; improved global functioning

Villeneuve82 Open-label 23 12 weeks Decreased impulsivity/hostility, depression/anxiety; improved global functioning

Bellino83 Open-label 14 12 weeks Decreased impulsivity/anger/
anxiety; improved social functioning

O, olanzapine; F, fluoxetine; DBT, dialectical behavior therapy; NA, not available.

– See more at: http://www.psychiatrictimes.com/articles/mood-stabilizers-and-novel-antipsychotics-treatment-borderline-personality-disorder/page/0/2#sthash.2YktoHMq.dpuf

Posted in News & updates | Leave a comment

Mood Stabilizers and Novel Anti psychotics in the treatment of Borderline Personality Disorder

Part #1

Borderline personality disorder (BPD) is characterized by a pervasive pattern of instability of interpersonal relationships, self-image, and affect, in addition to marked impulsivity.1 Although psychotherapy plays a significant role in the treatment of borderline patients by focusing on maladaptive personality traits and patterns of interpersonal relationships, 2,3 pharmacotherapy is indicated by the American Psychiatric Association guidelines to manage vulnerability traits, symptoms, and crises.4

Treatment strategies for BPD target different domains of psychopathology, such as cognitive-perceptual, affective, and impulsive-behavioral symptoms. Guidelines specify the use of antidepressant agents—in particular, selective serotonin reuptake inhibitors (SSRIs) and monoamine oxidase inhibitors—and mood stabilizers for affective dysregulation; SSRIs and mood stabilizers for impulsive-behavioral dyscontrol; and antipsychotics for cognitive-perceptual symptoms. This article focuses on data concerning the efficacy of mood stabilizers in the treatment of BPD.

The role of mood stabilizer

A consensus definition of mood stabilizer remains to be established, and international regulatory authorities do not officially recognize the term as a mode of drug activity.5 Clinicians and researchers apply the concept of mood stabilization to a range of compounds used in the treatment of bipolar disorder, although considerable variability can be found in the literature concerning the meaning and use of the term.6-11 In its broadest form, a mood stabilizer has been operationally described as an agent that is useful in at least 1 of the 3 phases of bipolar disorder (mania, bipolar depression, or long-term maintenance) while not increasing the frequency or severity of any of the other phases of the illness.6

Although no drugs used as mood stabilizers have been approved by the FDA for the treatment of BPD, these drugs are often prescribed off-label in clinical practice and are suggested for treating BPD-related symptoms by the guidelines of the American Psychiatric Association.4 Some investigators have proposed that the same mechanism may drive both the affective instability of BPD and the rapid mood cycling of bipolar disorder and that this could be a rationale for the use of mood stabilizers in BPD.12

To date, several open-label and controlled trials have been undertaken to test the efficacy of these agents in BPD and to define their effects on different dimensions of borderline psychopathology (Table 1).

Lithium carbonate

The first mood stabilizer considered for the treatment of patients with BPD is lithium carbonate; its effectiveness has been reported in 3 reviews since the late 1980s.13-15 Concerning the mechanism of action, 3 interacting systems appear critical for lithium activity: modulation of neurotransmitters, which may contribute to neuroprotection by readjusting excitatory and inhibitory activity balance; modulation of signals impacting on the cytoskeleton, including glycogen synthase kinase-3β, cyclic AMP-dependent kinase, and protein kinase C, which may be critical for the neural plasticity involved in mood stabilization; and regulation of second messengers, transcription factors, and gene expression.16

The results of a 6-week, doubleblind, placebo-controlled crossover study that compared lithium with desipramine in 10 patients with BPD showed the efficacy of lithium on core features of borderline psychopathology, such as irritability, anger, and selfmutilation.17 A review by Stein18 concerning lithium and the anticonvulsant agent carbamazepine in the treatment of patients with BPD or antisocial personality disorder pointed out the effectiveness of both agents on behavioral dysregulation and aggressiveness.

Carbamazepine

At about the same time, further data concerning treatment of BPD with carbamazepine were published. This agent blocks voltage-gated sodium channels and is indicated by the FDA as an anticonvulsant.19 Although its use in the treatment of BPD is common in clinical practice, this has not been officially approved. In a crossover trial with a sample of 11 female outpatients with BPD, Gardner and Cowdry20 demonstrated decreased frequency and severity of behavioral dyscontrol. Their results were confirmed by other studies: a 6-week controlled investigation comparing carbamazepine (mean dose, 820 mg/d), alprazolam (4.7 mg/d), trifluoperazine (7.8 mg/d), and tranylcypromine (40 mg/d) in the treatment of 16 patients with BPD and comorbid hysteroid dysphoria,21 and a review of double-blind clinical trials.22 Both showed that carbamazepine induced a marked improvement in impulsive aggression.

Controlled trials suggest the efficacy of carbamazepine not only in reducing impulsive-aggressive behaviors23 but also on affective dysregulation,24,25 which is often the main goal of mood stabilizer use in the treatment of BPD. A clinical practice survey by Denicoff and colleagues26 compared carbamazepine with many other agents (lithium, valproate, neuroleptics, clonazepam, phenytoin, calcium antagonists) and electroconvulsive therapy in 1257 patients with different neurologic and psychiatric disorders, and found a significant global improvement in the subgroup of patients with BPD treated with carbamazepine.

Table 1

Correlations of levels of damage

Agent Study
Design Number of
Patients Treatment
Duration Results

Lithium
Links17 Crossover vs desipramine 10 6 weeks Decreased irritability/anger, self-mutilation

Stein18 Review NA NA Decreased behavioral dyscontrol,
aggressiveness

Carbamazepine
Gardner20 Crossover vs placebo 11 NA Decreased behavioral dyscontrol

Cowdry21 Double-blind
vs ALP, TFP, TCM 16 6 weeks Decreased behavioral dyscontrol

Denicoff26 Retrospective vs other drugs and ECT 1257 NA Global

improvement

Oxcarbazepine
Bellino41 Open-label 13 12 weeks Decreased global symptomatology,
mood instability, impulsivity/anger,
interpersonal sensitivity

Valproate
Wilcox43,44 Case series NA NA Decreased global symptomatology,
anxiety/agitation

Stein45 Open-label 11 8 weeks Decreased anger/impulsivity, irritability

Kavoussi46 Open-label 10 8 weeks Decreased impulsive aggression,
irritability

Hollander47 Double-blind vs placebo 16 10 weeks Decreased global symptomatology, irritability/
aggressiveness;
improved social functioning

Hollander48 Double-blind vs placebo 52 12 weeks Decreased impulsive aggression

Frankenburg49 Double-blind vs placebo 30 6 months Decreased interpersonal sensitivity, anger/hostility, aggressiveness

Lamotrigine
Pinto51 Open-label 8 1 year Decreased behavioral dyscontrol;
improved global functioning

Green52 Review NA NA Decreased mood instability

Preston53 Retrospective 14 NA Decreased mood instability, impulsivity

Tritt54 Double-blind vs placebo 24 8 weeks Decreased anger

NA, not available; ALP, alprazolam; TFP, trifluoperazine; TCM, tranylcypromine; ECT, electroconvulsive therapy.

– See more at: http://www.psychiatrictimes.com/articles/mood-stabilizers-and-novel-antipsychotics-treatment-borderline-personality-disorder#sthash.ptXM4Cv8.dpuf

Posted in News & updates | Leave a comment

Adverse Effects Anti Psychotics and Mood Stabilizers

Although psychotropic medications have revolutionized the treatment of many psychiatric disorders, the benefits sometimes come at a price. Unwanted adverse effects may limit the use of these agents and may, in some instances, result in serious morbidity and mortality. In recent years, the adverse effects of second-generation antipsychotics on body weight have become a significant concern for clinicians and their patients; however, other metabolic effects of these drugs, as well as metabolic effects of first-generation antipsychotics and mood stabilizers, also require our attention and awareness. In this article we focus on the phenomenology, evaluation, and management of endocrine and metabolic adverse effects of these commonly used psychotropic agents.

Lithium and thyroid function

At therapeutic serum levels, the main action of lithium is to inhibit hormone release from the thyroid gland, which may result in hypothyroidism. Patients with underlying Hashimoto thyroiditis or radiation-induced thyroid injury may be particularly susceptible to this inhibitory effect.1 In adults, the prevalence of lithium-induced hypothyroid-ism generally increases with longer duration of therapy–about 20% of women and 5% of men are affected with hypothyroidism after 10 years of continuous treatment.2 The results of a pediatric study also suggest that patients taking both lithium and valproate may be at particularly high risk of having hypothyroidism develop, since the weak inhibitory action of valproate on the thyroid may synergize with the effects of lithium.3

Patients should have baseline thyroid function tests (at least for serum thyroid-stimulating hormone [TSH]) performed before beginning lithium treatment; since lithium-induced hypothyroidism may occur at any time during lithium therapy.1-3 Tests should be repeated 1 to 2 months, 6 months, and 12 months after starting lithium, and yearly thereafter. If hypothyroidism occurs during lithium treatment, replacement thyroid hormone therapy with levothyroxine should be started, and the dosage increased as needed to normalize serum TSH. Since lithium-induced hypothyroidism may occasionally be transient, it may be useful to try to slightly decrease the daily thyroxine dose after several years of treatment; if the serum TSH remains normal on the lower dose, further dose reductions may then be attempted.1

Lithium and parathyroid function

Mild hypercalcemia may develop in patients receiving lithium, generally in the range of 10.5 to 11.5 mg/dL, with normal or mildly elevated serum levels of parathyroid hormone, usually along with decreased urinary calcium excretion. This constellation of abnormalities appears to be due to a lithium-induced loss of sensitivity of the parathyroid calcium-sensing receptor; the parathyroid gland perceives a higher than normal serum calcium level as normal, and parathyroid hormone secretion is regulated around an elevated set point.4 About 5% of patients receiving long-term lithium therapy have been found to have hypercalcemia.5,6 The hypercalcemia is usually not progressive, and kidney stones are uncommon (since the patients are usually hypocalciuric).

Although the hypercalcemia is usually reversible if lithium is discontinued, in some instances it has been persistent, and parathyroid adenomas or multigland parathyroid hyperplasia have been found in some patients with lithium-induced hypercalcemia.7 Because hypercalcemia may occur at any time during lithium therapy,4-7 serum calcium should be measured 1, 6, and 12 months after starting lithium, and yearly thereafter. If serum calcium levels exceed 11.5 mg/dL or if clinical signs and symptoms of hyperparathyroidism (eg, fatigue, nausea, constipation, worsening osteoporosis) develop, lithium may need to be discontinued.

Antipsychotics and hyperprolactinemia

Prolactin secretion is primarily regulated through the suppressive action of dopamine, which is secreted from hypothalamic neurons and delivered to the anterior pituitary through the hypothalamic-pituitary portal blood vessels. Medications that block the pituitary dopamine D2 receptor will interfere with this tonic inhibitory effect of dopamine and thereby increase serum prolactin levels. Most typical (first-generation) and some atypical (second-generation) antipsychotics raise serum prolactin acutely; after the initial rise, serum prolactin frequently declines gradually (months to years), and in some cases may return to normal, despite continued administration of the drug.8

The atypical antipsychotic agents are variable in their effects on prolactin, since they vary in their affinity for the pituitary dopamine D2 receptor. One of the atypical agents, aripiprazole, acts on the dopamine receptor as a partial agonist (which lowers serum prolactin levels). Women tend to have higher prolactin responses to antipsychotics than men because estrogen stimulates prolactin synthesis and responsiveness.9 The approximate relative potency of antipsychotics in causing hyperprolactinemia is (in order of decreasing potency) risperidone, haloperidol, olanzapine, ziprasidone, quetiapine, clozapine, and aripiprazole.

Prolactin acts on the hypothalamus to suppress the secretion of gonadotropin-releasing hormone, which results in decreased secretion of luteinizing hormone and follicle-stimulating hormone and, ultimately, hypogonadism. In women, the hypogonadism is manifest most commonly as secondary amenorrhea and infertility; decreased libido and osteoporosis can occur in both women and men as a result of decreased gonadal production of sex steroids. Breast enlargement and breast pain can be seen in both men and women; galactorrhea is more common in women, who have estrogen-primed breasts. Although hyperprolactinemia-induced hypogonadism might be expected to slow pu- bertal development, normal pubertal progression over a 12-month period was observed in the only study to date that specifically addressed this issue.10 Erectile dysfunction may also occur, perhaps as a direct effect of prolactin on the nervous system11 as well as an effect of hypogonadism.

A recent study based on adverse-event reports submitted to the FDA has suggested that antipsychotic-induced hyperprolactinemia may be associated with an increased incidence of benign, presumably prolactin-secreting pituitary adenomas.12 There were 77 cases of pituitary tumors reported in patients taking antipsychotic agents; 54 of these involved risperidone, the drug with the greatest propensity to cause hyperprolactinemia. Although a caus-al relationship cannot be excluded, it seems more likely that symptomatic hyperprolactinemia developed in patients receiving antipsychotics, particularly risperidone, who then underwent MRI scanning of the pituitary as part of a diagnostic evaluation. Since incidental pituitary tumors (usually nonfunctioning) are found on MRI scans in about 10% of the general population,13 the tumors found in the patients treated with antipsychotics may bear no relationship to the drug therapy.

During drug therapy, the physician should inquire about menstruation, nipple discharge, breast enlargement, sexual functioning, and (if appropriate) pubertal development. If these are normal, there is no need to measure serum prolactin. However, if problems in these areas are uncovered that are temporally related to antipsychotic therapy, serum prolactin level should be measured.

If the level of serum prolactin is elevated but less than 200 ng/mL in a symptomatic patient, other causes of hyperprolactinemia (such as pregnancy, hypothyroidism, and renal failure) should be excluded by measuring serum human chorionic gonadotropin, TSH, and creatinine levels. If these tests are negative, one might try to decrease the dosage of the antipsychotic medication or change treatment to an agent less likely to elevate serum prolactin. If it is not possible to lower the dosage or switch to a different medication, it may be helpful to add a small dose of aripiprazole, which will usually suppress serum prolactin by virtue of its partial dopamine-agonist properties.14 Dopaminergic drugs, such as bromocriptine or cabergoline, can also be given but may occasionally worsen the underlying psychosis.15

If the serum prolactin level is greater than 200 ng/mL or remains elevated despite a change to a prolactin-sparing agent, an MRI scan of the sella turcica should be performed to exclude a pituitary or parasellar tumor. If the appearance on the MRI scan is normal, one might add aripiprazole or bromocriptine (as above), prescribe sex steroids (eg, oral contraceptives for women of menstrual age, testosterone for men), or give drugs to prevent osteoporosis (eg, bisphosphonates).9

Valproate and polycystic ovary syndrome

Polycystic ovary syndrome (PCOS) is defined as chronic anovulation and hyperandrogenism, with or without actual polycystic ovaries. Although not all PCOS patients are obese, insulin resistance is the norm, even in patients of normal weight.16 Recent reports have suggested that women of menstrual age who received valproate were at increased risk for the development of PCOS, characterized by oligomenorrhea, increased serum androgens with resulting hirsutism and acne, and, in some cases, a polycystic ovarian morphology seen on pelvic sonography. Joffe and colleagues17 recently reported that PCOS developed in about 10% of women with bipolar disorder who were started on valproate therapy (compared with 1.5% of women treated with lithium and other antiepileptic mood stabilizers), most within the first 6 to 12 months of treatment.

In vitro studies have demonstrated a direct action of valproate on ovarian tissue to increase the expression of androgen biosynthetic enzymes, resulting in increased ovarian production of androgens.18 Both valproate and drug-induced weight gain appear to raise serum insulin levels; the resulting hyperinsulinemia further stimulates ovarian androgen production.17,19

Patients should be counseled about diet and exercise at the start of valproate therapy in an effort to avoid weight gain since obesity will worsen insulin resistance and hyperandrogenemia.16 At each visit, patients taking valproate should be asked about menstrual irregularity, hirsutism, and acne. If these are present, the patient should be referred to a gynecologist or endocrinologist for further evaluation and treatment. Therapy for PCOS may include an oral contraceptive or progestin, insulin sensitizers such as metformin, antiandrogens, and local/topical treatments for hirsutism and acne. Since other mood stabilizers such as lithium and lamotrigine do not appear to cause PCOS, a switch to either one of these medications could also be helpful.17

Antipsychotics and metabolic adverse events

Recently, the focus on the tolerability of antipsychotics has shifted from extrapyramidal syndrome (EPS) toward adverse effects on body weight and related metabolic consequences that seem to be more common with atypical than with typical antipsychotics.20 The concerns about weight gain are fueled by ample evidence that increased body weight and obesity, particularly increased visceral fat agglomeration, are associated with greatly increased risks for diabetes, dyslipidemia, and hypertension (the metabolic syndrome; see Table 1) and are related to increased coronary heart disease morbidity and mortality.21,22 In addition, antipsychotic-induced weight gain has been associated with a lower quality of life23 and impaired medication adherence.24

Data suggest that there is an increased prevalence of obesity, diabetes, and dyslipidemia in patients with schizophrenia and bipolar disorder compared with the general population. Increased relative risk estimates range from 2 to 3 times the risk for obesity25,26 and diabetes27,28 to 4 to 5 times the risk for dyslipidemia.22 Likewise, prevalence rates for the metabolic syndrome and for calculated 10-year coronary heart disease events have been shown to be about twice as high in patients with schizophrenia29-31 and in patients with mixed diagnoses receiving atypical antipsychotics.32 Rates in patients with bipolar disorder have also been higher than in the general population, although they seem to be less elevated than in patients with schizophrenia.33

Antipsychotic effects on body weight and glucose and lipid metabolism

The elevated rate of physical disorders in patients with mental illness is probably the result of a complex interaction of genetic, psychiatric, lifestyle, and treatment factors. Within this multifactorial etiology, medications contribute to weight gain and adverse metabolic outcomes to varying degrees. Clozapine and olanzapine have been shown to have the greatest propensity to lead to weight gain and obesity; quetiapine and risperidone rank intermediate; and, at least in studies of adults with the most extensive antipsychotic treatment histories, ari-piprazole and ziprasidone appear to be least associated with adverse effects on body composition.21,34

Since weight gain and obesity are associated with increased rates of diabetes and lipid abnormalities in the general population, it is not surprising that atypical antipsychotics have been shown to increase glucose and lipid levels.21 In general, the adverse effect of the atypical agents on glucose and lipid metabolism follows the order of magnitude of weight gain.20,21,34 However, several recent studies suggest that clozapine and olanzapine, at least, may also have weight-independent, “direct” adverse effects on glucose homeostasis.35,36

Mechanisms of weight gain

Unfortunately, the exact mechanisms of antipsychotic-induced weight gain are unclear. While increased caloric intake is the most favored hypothesis,37,38 decreased resting metabolic rate and energy expenditure have also been proposed, although studies have shown mixed results.39,40 Proposed mechanisms for these effects include blockade of various neurotransmitter receptor systems, including histamine, serotonin, and a- and b-adrenergic receptors. It is unclear to what degree antipsychotics also interact with any of the multiple hormones and neuropeptides that are relevant for food intake and energy homeostasis.38

Monitoring and management

Since the greater recognition of the metabolic risk of atypical antipsychotics, monitoring guidelines have been proposed around the world.41 In the United States, the American Diabetes Association guidelines20 and Mt Sinai guidelines42 are the most prominent. These guidelines recommend baseline assessments of family history of metabolic syndrome components, as well as the assessment in each patient of height and weight, waist circumference, blood pressure, and fasting glucose and lipid levels (Table 2).

Weight should be checked monthly for the first 3 months and quarterly thereafter. Blood pressure and fasting glucose and lipid levels should be checked at 3 months and then annually (even though earlier recommendations had proposed measurements every 5 years if lipid levels were normal at 3 months20). More frequent assessments are recommended for patients with metabolic risk factors, including a family history of diabetes or early cardiovascular death, and/or marked weight gain.

Monitoring early weight gain can also be helpful to identify high-risk patients because early weight gain strongly predicts continued weight gain.43 Furthermore, the presence of abdominal obesity (ie, waist circumference greater than 40 inches in men and greater than 35 inches in women) had a greater than 90% sensitivity for identifying patients receiving atypical antipsychotics who fulfilled criteria for the metabolic syndrome.44

Measures to attenuate or reverse medication-induced weight gain and metabolic complications include healthy lifestyle education and behavioral weight loss interventions9,45-47 or pharmacological augmentation with a weight loss agent, such as metformin,48 sibutramine,49 orlistat,50 to-piramate,51 amantadine,52 or bupropion.53 An alternative for the potential reversal of antipsychotic-induced weight gain and metabolic consequences is to switch the patient to an antipsychotic with a lower metabolic burden.54-56 However, in the absence of reliable response predictors, the most cost-effective and simple preventive measure is to begin treatment with a lower metabolic risk agent and to use higher metabolic risk antipsychotics only in those patients who do not benefit from this medically driven treatment choice.

Summary

Balancing effectiveness of psychotropic medications with their potential for adverse effects is a crucial component of the successful treatment of mental disorders. With few exceptions (eg, diabetic ketoacidosis), endocrine and metabolic side effects are in many ways less acute and overt than other commonly observed adverse effects, such as sedation, EPS, and anticholinergic disorders. However, disruption of normal endocrine function can have serious long-term consequences. Therefore, clinicians need to be fa-miliar with potential adverse effects and be prepared to implement appropriate monitoring and management strategies.

Drugs Mentioned In This Article

Amantadine (Symmetrel)

Aripiprazole (Abilify)

Bromocriptine (Parlodel)

Bupropion (Wellbutrin, Zyban)

Cabergoline (Dostinex, Cabaser)

Clozapine (Clozaril)

Haloperidol (Haldol)

Lamotrigine (Lamictal)

Levothyroxine, Thyroxine (Synthroid, others)

Lithium (Eskalith, Lithane, Lithobid)

Metformin (Glucophage, others)

Olanzapine (Zyprexa)

Orlistat (Xenical)

Quetiapine (Seroquel)

Risperidone (Risperdal)

Sibutramine (Meridia)

Topiramate (Topamax)

Valproate/Valproic acid (Depakote, others)

Ziprasidone (Geodon)
– See more at: http://www.psychiatrictimes.com/adverse-effects-antipsychotics-and-mood-stabilizers#sthash.Njd3RrTO.dpuf

Posted in News & updates | Leave a comment

Mood Stabilizers and Mood swings : In search of a definition

Mood-stabilizing drugs slipped into the vocabulary of psychiatrists during the last 15 years without a proper discussion of their definition. Consequently, these medications have been used in ways that have no empirical justification. The original idea behind the term mood stabilizer was the apparent ability of lithium to offer antimanic qualities as well as some measure of antidepressant action. The American Psychiatric Association’s Practice Guideline for Treatment of Patients With Bipolar Disorder (1994) defines mood stabilizers as “medications with both antimanic and antidepressive actions.

” From time to time, research has been contradictory about the efficacy of lithium as an antidepressant (Keck and McElroy, 1996). However, the concept was clear. This is not the case with the various anticonvulsant medications that have been labeled mood stabilizers. Despite widespread use, it is not obvious what is meant by a mood stabilizer and how anticonvulsants fit that description.There is little if any clear-cut evidence that valproate (Depakote, Depakene), carbamazepine (Tegretol) (Kalin, 1996-1997) or gabapentin (Neurontin) are effective antidepressant agents. Yet as soon as they were shown to have efficacy in acute mania, they were quickly labeled mood stabilizers rather than antimanic agents.This is not a matter of small significance, since it is not unusual for bipolar patients with a predominantly depressive history to be exclusively put on mood stabilizers with the expectation that the depression will be treated, and that rapid cycling due to the use of traditional antidepressants will be avoided.

I’m not referring to the prophylactic use of mood-stabilizing agents when it is expected that antidepressants will later be necessary so that protection against a potential manic episode seems judicious. Frequently, mood stabilizers are used as the sole antidepressant. Indeed, an expert consensus treatment protocol recommends mood stabilizers alone as a first-line approach in treating milder major depressive episodes in bipolar I disorder and as a second-line approach in bipolar II disorder (Frances et al., 1996).Some experts such as Bowden (1996) and Keck and McElroy (1996) are so concerned about the possibility of rapid cycling that they go still further, considering the use of antidepressants as a last resort in treating bipolar depression only after multiple mood stabilizers have been tried first. While the concern about antidepressants causing rapid cycling is based on an indisputable clinical possibility, these experts have no illusions about the effectiveness (or indisputable evidence for the effectiveness) of anticonvulsant medications as treatment for acute bipolar depression. Both valproate and carbamazepine did little better than placebo in the studies they cited, but if I understand them correctly, they considered bringing relief from the torment of depression as quickly as possible a less important priority than not iatrogenically causing mood instability.According to Gary S. Sachs, M.D., the definition of the term mood stabilizerdoes not require antidepressant or antimanic efficacy, per se, merely that the medication “decrease vulnerability to subsequent episodes of mania or depression” and not exacerbate the current episode or maintenance phase of treatment (1996).

The use of anticonvulsant medicines as mood stabilizers has become even more relevant since the expansion of the bipolar disorder (BD) diagnosis to include bipolar II patients (American Psychiatric Association, 1994). Bipolar II is a reasonable addition to the nosology of mood disorders, sometimes allowing earlier recognition and an appropriate alertness to the softer signs of the illness. However, it also has contributed to an excessive looseness in diagnosing BD. On more than one occasion, I have had patients hospitalized for severe depression and, after a three- or four-day stay, they have returned on a mood-stabilizing agent and nothing else. They have been told that they have bipolar disorder and that their anticonvulsant medication treats the basic problem.Here is an example.Ariel, a 16-year-old girl, had a history of repeated severe suicidal depressions punctuated by periods of a few hours, sometimes a day or two (definitely not four days as specified in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition for hypomania), in which she felt a bit giddy as well as more social, energetic and creative. There was no family history of manic-depressive illness. She did not feel that her “up” times were a problem. Indeed, she was able to perform at a high level academically and felt more connected to her friends and parents. There was no pressured speech, flight of ideas or a sense that her mind was racing.

There was no distractibility; impulsivity; irresponsible spending, driving or sexual behavior; or loss of judgment. Insomnia was not present, and there was no history of a decreased need for sleep. Although there was an improvement in self-esteem, it was not inflated or grandiose. Ariel’s parents and friends, as well as Ariel herself, considered her good moods entirely normal and delighted in them.The arguments for and against using a loose definition of BD hinge on the risk/benefit ratio of active treatment. On the benefit side, at least theoretically, is the kindling model for bipolar disorder. It is hoped that the prevention of frequent manic episodes may prevent rapid cycling that often develops later in the illness. But this is theory, not fact. Even when the diagnosis is clearly bipolar, there’s no empirical documentation and no longitudinal studies that demonstrate long-term administration of medications will prevent rapid cycling later in the illness. Despite this lack of proof, when a bipolar diagnosis is unequivocal, treatment is a no-brainer. We treat vigorously with the hope there will be this eventual benefit because good acute control is desirable anyway.When the diagnosis is based on looser criteria, it is a more complicated issue. There are at least two prospective studies demonstrating that patients with major depressive disorder and a definite family history of BD have a very high risk for transformation to bipolar I disorder (Akiskal et al., 1983; Strober and Carlson, 1982). Clearly in this situation, it is advisable to monitor patients with serious depression closely for early signs, even more so when there are soft signs of hypomania. But if there is no family history, a case can be made to hold back on treating the patient’s not diagnostically definable highs.From this vantage point, if a patient such as Ariel does not have symptoms that she, her family and friends, or any layperson, would consider symptoms, what are we treating? If we believe that we are somehow correcting a fundamental chemical imbalance, there would be a rationale. But we don’t know what the chemical imbalance(s) is (are) in bipolar disorder.

We don’t really know what mood stabilizers do for the illness. Even our guesses hint at diverse possibilities. Thus, valproate seems to have an effect on ?-aminobutyric acid (GABA) receptors, and gabapentin may increase brain levels of GABA. In contrast, the proposed mechanism of action for carbamazepine and lamotrigine (Lamictal) is voltage-dependent inhibition of sodium currents. The latest speculations about lithium are that it is affecting G-proteins, that it exerts a push/pull effect on the neurotransmitter glutamate (Dixon and Hokin, 1998; Lenox et al., 1998), or that it alters sodium transport in nerve and muscle cells and effects a shift toward intraneuronal metabolism of catecholamines (Physicians’ Desk Reference, 1999).Diverse research hypotheses are a good thing, but they are not the same as hard knowledge. How can we argue that we are treating at a fundamental, etiological level of the illness when we don’t know what the chemical problem is, when our best guesses about how various mood stabilizers work are that they work differently from each other, and when we don’t know how these proposed mechanisms might or might not be related? Moreover, we don’t have clear proof that we will prevent the eventual development of the DSM-IV illness; even in the treatment of the DSM-IV illness, we don’t yet know if we are altering its long-term course. All we do know is that we have good-not great-medications that help control symptoms.Hagop S. Akiskal, MD, makes the strongest argument for a liberal view of a very broad bipolar spectrum of abnormalities. He believes DSM-IV is far too limiting and would include a bipolar III and a variety of conditions under the bipolar umbrella (Akiskal, 1996; Akiskal and Mallya, 1987). This position is not absurd in the sense that when we eventually understand the genetics and biology of manic-depressive illness, we may discover fundamental relationships.

However, DSM-IV is not a true collection of illnesses defined by etiologies. It is a collection of disorders about which committees decide certain symptoms should be clustered with the hope that someday, true etiological understanding will correlate with these clusters or future clusters as the evidence indicates. The issue here is using medications that may only be working on symptoms (and possibly or probably not etiology or pathogenesis) in patients who do not have symptoms as defined by themselves or reasonable laypeople. In Ariel’s case, she was suffering from depression and was given a treatment that has not been shown to be effective for depression.On the risk side of the equation, the danger of unnecessary medication is obvious with carbamazepine because of the possibility of aplastic anemia and agranulocytosis. While this is rare (six patients per 1 million population per year for agranulocytosis and two patients per 1 million population per year for aplastic anemia), if carbamazepine is used by enough psychiatrists over enough years for unjustifiable purposes, there will be deaths that might not have occurred. In the case of valproate, hair loss, weight gain, fatigue and, most recently, the threat of polycystic ovaries, favors caution in a patient such as Ariel.

Tiredness and, sometimes, hypersomnia are not uncommon even at therapeutic levels and contribute to treatment noncompliance. A huge number of patients whom I have followed after inpatient stays with an equivocal diagnosis are sleeping 14 hours a day. Of course, it does not help that locally the standard regimen resulting from these hospitalizations seems to also include Zyprexa (olanzapine).Ariel did have “mood swings.” She would be in a perfectly good mood and then suddenly, with relatively minor provocation, switch to sadness, irritability or an outburst of anger.

This was the other major justification for placement on a “mood stabilizer.” There’s only one problem with this. The use of the term mood swingsin bipolar disorder has usually referred not to labile affect, but to relatively long stretches of depression or mania lasting weeks or months-although occasionally days-which would then swing to the opposite.While it is true that mixed episodes are not rare and may be characterized by very rapid shifts in mood over the course of a day, mixed episodes may also consist of a vague blending of both euphoric and dysphoric themes. In any case, until recently, the term, mood swings, did not refer to volatile moods.Apparently, however, without a discussion in the literature of this changed definition, mood swings have come to mean labile affect. Similarly, rapid cycling-defined in the DSM-IV as four or more switches in a year-not infrequently appears in clinical summaries when what is being described are labile moods.At first, I thought the problem was our local inpatient unit and a mistaken reading of DSM-IV by one doctor in particular. If that were the case, there would be no reason for this article. It soon became apparent that similar diagnoses were being made at three other inpatient units that I have contact with, including two prominent academic centers.

I have questioned several nurses on these wards and learned that most misbehaving, impulsive teen-agers (once characterized as rebellious) are now being diagnosed as bipolar. At an outpatient alcohol rehabilitation center, a counselor told me the same thing was happening there. Erratic moods and behavior were being called mood swings, and thus had become bipolar symptoms. Moreover, the new use of the term mood swings had been embraced by the other psychiatrists in town who were doing strictly outpatient work. Social workers and psychologists were asking, as never before, for medication evaluations for bipolar disorder on the basis of mood swings, and many patients were self-referring themselves for mood swings, having read about them on the Internet.The typical story I heard when I questioned a patient with mood swings was something like the following: “I’d be in a perfectly good mood at a party but then would feel like going home. When my boyfriend gave me a hard time, I’d let him have it.” Or, “I would be doing fine shopping at the supermarket. Suddenly, someone would cut in front of me in line, and I’d go ballistic.” Or, “I’d be getting along with my parents at home. Then my father would say something, and I’d go stomping off to my room.” Sometimes, there would be no external event at all, but the patient would notice a dramatic shift in mood from when they woke up feeling fine to later in the day when they were feeling down.Generally, in all of these cases the patients had almost no introspective capacity. They had never attempted on their own, or been encouraged by their psychiatrist, to make sense of the personal meaning of their father’s comment, or why their boyfriend made them so angry by refusing to come home from the party and so forth. As far as they were concerned, their behavior was totally incomprehensible and beyond their control. They were relieved to hear that the explanation for their difficulty was a chemical imbalance because, not only would it no longer be their fault, but just as importantly, it could now be fixed.Undoubtedly, over time, some of the impulsive and/or moody adolescents now being diagnosed bipolar II on the basis of their mood swings will later prove to be suffering from manic-depressive illness.

This may turn out to be true of Ariel.Kramlinger and Post (1996) described clear-cut bipolar patients who were followed on a ward and rated for mood every two hours during the course of a day. They found a group of five patients who went up and down throughout the day and wondered whether these represented “ultra-ultra rapid cycles or ultradian cycling.” However, this interesting observation is a far cry from the routine labeling of volatile patients as bipolar.There is another contributing issue to what I believe is the overdiagnosis of BD. In addition to “mood swings” being used as the basis for diagnosis, irritability has gained new status. It has always been appreciated that irritability, rather than euphoria, can be part of a manic episode. But one would assume that irritability by itself would not be the basis for diagnosing bipolar disorder in an unhappy teen-ager or depressed individual, especially since irritability is found much more commonly in depression than in mania. However, I am discovering that many psychiatrists are using this criterion quite freely, especially with patients who have labile affect, and are basically making the diagnosis on a hunch.Although the considerations above regarding risk/benefit ratio still apply, ordinarily I would have no difficulty with a clinician following a clinical intuition and diagnosing atypical BD now and again when full criteria were not met. The problem is, if my observation of local practice patterns hold elsewhere, such hunches have become routine, especially in the rapid-turnover inpatient wards that now characterize our mental health system. It has become the diagnosis du jour. Observing practice patterns in Penn Valley, Pa., psychiatrist David Behar, MD, in a letter to Clinical Psychiatric News (1998) described bipolar disorder as being absurdly overdiagnosed. “Any overreacting patient now gets the label and a mood stabilizer,” he said.If this is the case nationally and not just in the Northeast, it is reasonable to look for an explanation. We also must include the pressure on outpatient psychiatrists from referring therapists who themselves are under pressure from health maintenance organizations and mass media articles that foster patient expectations of rapid results. The psychiatrist is placed in a situation not dissimilar to some family doctors who would prescribe antibiotics for the common cold so the patient would feel the doctor “did something.”

Pressure also comes from the occasional therapist who doesn’t like their diagnostic acumen questioned and will refer elsewhere if the patient doesn’t receive medication for mood swings. This can be likened to schoolteachers who want their unruly students labeled as having attention-deficit/hyperactivity disorder and Ritalin (methylphenidate) prescribed.Ultimately, the problem may be language itself. Even when a bipolar diagnosis, per se, is not considered, having a category of drugs called mood stabilizers lends itself quite well to a belief that it is a valid approach to moodiness. In this case, the issue is not whether anticonvulsant, antimanic medications deserve to be called mood stabilizers in bipolar disorder, but rather that the termmood stabilizers conveys the impression that they are a perfect fit for volatile, overemotional patients.As noted, alcohol and drug abusers are now very often being diagnosed with bipolar disorder, once again because labile affect, a common finding in alcohol and drug abusers, is being called mood swings. One factor contributing to this is our better appreciation of how many bipolar patients abuse alcohol and drugs. However, in the absence of a clear-cut history, I don’t know how a bipolar diagnosis can be made until the patient has been off intoxicants for a reasonable period of time. Rapid shifts in mood have always characterized the behavior of alcohol- and drug-abusing patients as well as those recovering from addiction. What is gained by the bipolar label? Some alcoholic patients like it because it “explains” their lack of control. Like genetic theories of alcoholism, it shifts blame and gives an external enemy to fight against. However, these should not be the reasons for us to make the diagnosis.Mood lability is also an important component of borderline personality disorder (BPD) and here, too, an unusual number of patients are being diagnosed bipolar on the basis of their mood swings. Granted one can legitimately make a case, as Akiskal does, that borderline personality disorder is fundamentally an affective disorder and possibly a variant of bipolar disorder (1996). In the case of BPD, the ravages of this diagnosis are so extreme, and so many of our treatments are ineffective, that I see nothing wrong with trying one of the anticonvulsant medications on an empirical basis. However, in my experience, high doses of selective serotonin reuptake inhibitors seem to work far better for labile affect, probably because of their ability to alleviate frustration and dull passions rather than from an antidepressant action, per se.To summarize, there are three important questions:1) Are rapidly shifting moods (now mislabeled as mood swings) particularly diagnostic of bipolar disorder?2) Are mood-stabilizing medications useful in patients with rapidly shifting moods whether or not they are truly bipolar?3) What is the mechanism of action of the anticonvulsant medications that make them useful in psychiatric conditions?Question 1:

I do not know if rapidly shifting moods are a typical feature of manic-depressive illness. My clinical impression, after close to 30 years of practice, is that they are not uncommon, both before other symptoms have become manifest and afterward. But rapidly shifting moods are far more common in the instances already discussed: unhappy or rebellious adolescents, alcoholics and drug abusers, and those with borderline personality disorder. Whether the mood changes during the course of a day seen in mixed episodes of bipolar patients constitute ultradian cycling or are simply what typically constitutes mixed episodes has to be settled (Kramlinger and Post, 1996).Regardless of the outcome of that issue, I think we have to address the separate issue of whether the presence of mood lability should raise our index of suspicion for manic-depressive illness in moody adolescents, borderlines, alcoholics and others with short fuses. (It should be emphasized that Kramlinger and Post’s ultradian cycling referred to ratings of mood systematically made every two hours and not sudden mood shifts.)Questions 2 and 3: Ironically, despite the unfocused use of the term mood stabilizer described earlier in this article, I think clinicians may have found a legitimate use for anticonvulsant medications in psychiatric practice. The literature includes theories that GABAergic mechanisms may play a role in depression (Petty, 1995; Petty et al., 1996). From time to time, various benzodiazepines have been claimed to have antidepressant efficacy. This might be due to the hypothesized fundamental chemical relationship between GABA and mood. Or, it might be an indirect result of their tranquilizing function. After all, patients with panic disorder often develop depression secondary to their lost sense of control and have an improvement in mood once benzodiazepines have put out the fires.

Similarly, some patients with agitated depressions experience anxiety as the most distressing part of their syndrome and find their mood improves, even before antidepressants kick in, when benzodiazepines have provided relief from their anxiety.If there is a fundamental relationship between GABAergic mechanisms and mood, then the use of valproate and gabapentin might eventually be empirically shown to have antidepressant action, and my earlier denigration of the term mood stabilizers would be misplaced. The term would legitimately apply to these anticonvulsant medications in its traditional sense. However, since carbamazepine and lamotrigine are not believed to work through GABAergic mechanisms, and they are mentioned in the same breath with the other mood stabilizers, my best guess is that the quality that anticonvulsant medications have in common is that they are calming agents or tranquilizers. They may represent the long-sought effective, nonaddicting tranquilizers. (There is some support for valproate’s anxiolytic-like function in animal research [Dalvi and Rodgers, 1996; de Angelis, 1995].)On an intuitive level, it makes sense that anticonvulsant medicines, whatever their mechanism of action, are calming. Indeed, if we picture seizures as “a massive discharge of neurons,” it is not much of a stretch to think of the various psychiatric conditions where anticonvulsant mechanisms are finding particular usefulness-explosive disorder, mania, panic disorder, borderline personality disorder-as conditions that may possibly have analogous massive discharges of nerve impulses.

And one step down from that, one could imagine that mood swings, as the term is being used today for those with fiery temperaments, or those caught in the storms of adolescent turmoil, might be attenuated by calming agents, with or without a bipolar diagnosis. In other words, mood stabilizers help mood swings, as the terms are being misused today. Eliminate calling the patients bipolar and not that much harm is done. Valproate may deserve its widespread usage.We are still left with the question of whether anticonvulsant medications’ calming action is necessarily working directly on mood. This question is of some relevance because of the kind of backward reasoning that seems to accompany the effective use of anticonvulsant medications. For example, Stephen J. Donovan, M.D., has proposed that a new diagnosis-explosive mood disorder (EMD)-be created and replace the diagnoses of conduct disorder or oppositional defiant disorder in one subset of patients-children with irritable mood swings-“because these are sociological not psychological constructs. They do not identify what is ‘disordered,’ suggest etiology or guide treatment” (Sherman, 1998). And what was Donovan’s basis for suggesting that the primary difficulty is mood? Adolescents meeting the EMD criteria improved on the mood stabilizer divalproex.Similarly, because such agents as valproate and carbamazepine have been found useful in recovering alcoholics does not necessarily support a view that these patients are probably bipolar. Rather, the patients’ improvement might be the result of these agents’ tranquilizing function. This kind of thinking is entirely separate from whether or not anticonvulsant medications have an antidepressant action.Going out on a limb, I would argue that even in bipolar disorder, the various anticonvulsant medications being used to control mania may not be directly treating the elevated mood, per se, but rather treating the intensity of mania, the exuberance of energy, racing thoughts and the like.

Just as patients with panic disorder often feel less dysphoric when they regain control through the use of benzodiazepines, it is possible that mood stabilizers could, with chronic administration, be demonstrated to have an indirect antidepressant action by returning a measure of self-control, rather than through a direct antidepressant action. Certainly, many patients with BD rue the foolishness of their mania, not to mention the broken marriages, lost friendships and jobs, depleted bank accounts, and sheer havoc left in the wake of their exuberance. Over a period of time, less havoc would serve as one less stressor to precipitate dysphoria and depressive episodes.Also, I have treated several bipolar I (mixed) patients who resembled agitated depressives in their level of anxiety. Although admittedly a small anecdotal sample, my personal impression is that these are the only patients who have shown an antidepressant effect from divalproex. My guess would be that it is the calming effect of the divalproex that was helpful here rather than the antidepressant effect. Otherwise, from pure chance, I would have seen more cases in which the divalproex worked as an antidepressant. Moreover, considering the amount of research done, one would expect by now to see good double-blind evidence of divalproex antidepressant action (rather than the usual “soon to be published” impression) if the effect were a robust one. I am also curious if, within the studies showing that anticonvulsants have an acute antidepressant action (in the range of 30% to 40%), there are data that could be teased out regarding agitation. Did the responding patients have greater amounts of agitation than other depressed patients?Finally, before we get too excited about “better living through chemistry,” a word about mood swings of the adolescent variety. Classic psychoanalytic concepts are more relevant than ever. The vicissitudes of self-esteem regulation in many adolescents are closely linked to the loss of an idealized authority figure (and accompanying culture) from whom they can feel protection and confirmation. As they leave the cocoon of their own family’s world and values, they must replace it with a stark and uncertain court governed by peer approval. It is a faddish, unforgiving universe of shifting gurus and uncertain alliances that plays havoc with mood until, with maturity, a more stable identity can be established. This is not to mention the effect of changing hormones, astonishing physical growth and emergence of sexual passion. Medication may have a role to play during this transitional period. But I would hope that psychiatrists have the wisdom to guide parents and children appropriately through this difficult time, and not confuse matters with scary diagnoses such as bipolar disorder and the use of chemicals that work in ways that are poorly understood. – See more at: http://www.psychiatrictimes.com/mood-disorders/mood-stabilizers-and-mood-swings-search-definition#sthash.iBXP1blr.dpuf

Posted in News & updates | Leave a comment

Advance Directives

These vignettes describe two scenarios quite familiar to persons with severe mental illnesses and their families. Consumers frequently experience situations in which they are given little control over important treatment decisions. Families just as frequently are frustrated by having to stand by and watch their loved ones deteriorate and suffer.

Psychiatric advance directives have recently emerged as potentially helpful tools in resolving these problems. There are essentially two types of advance directives. Instruction directives”, such as living wills, provide specific information about treatment and related wishes of individuals drafting them (declarants) should they lose capacity to make these decisions on their own. “Proxy directives” assign “health proxies” or “health care powers of attorney” to individuals entrusted to act as substitute decision makers should declarants lose capacity to make their own decisions. Frequently, advance directives combine both of these forms, blending specific instructions about healthcare preferences with identification of individuals assigned “health proxies.”

Traditionally, advance directives have been used primarily for “end of life decisions,” for example, specifying the wishes of individuals to be withdrawn from life supports when there is no longer any reasonable hope of survival. In recent years, advance directives have been recognized as potentially helpful in empowering individuals suffering from mental illnesses to communicate treatment preferences in advance of periods of incapacity.

Supporters of psychiatric advance directives view these instruments as potentially helpful for at least four reasons. First, they can empower consumers to assume control over treatment decisions. Second, they can be very useful in enhancing communications about treatment preferences between consumers, their caring families, and treatment providers. Third, they may facilitate appropriate and timely treatment interventions before situations deteriorate to emergency status. Finally, they may lead to reductions in adversarial court proceedings over involuntary psychiatric treatment.

Laws authorizing certain forms of living wills or healthcare directives have been enacted in all 50 states and the District of Columbia. Many of these laws do not specifically reference psychiatric decision making, except that some of them expressly exclude decisions about certain types of psychiatric treatment such as inpatient treatment, Electro-Convulsive Therapy (ECT) or psychosurgery from their scope.

Laws specifically authorizing psychiatric advance directives have been enacted in twelve states. The first law authorizing psychiatric advance directives was enacted in Minnesota in 1991. Alaska, Hawaii, Idaho, Illinois, Maine, North Carolina, Oklahoma, Oregon, South Dakota, Texas and Utah have since followed suit. All of these laws establish the right of persons with mental illnesses to write directives, when competent, indicating their wishes concerning acceptance or refusal of psychiatric treatment. Some of these laws (e.g. Alaska and Oregon) apply only to written declarations concerning inpatient psychiatric treatment, psychotropic medications, and ECT. Others apply more generally to all forms of psychiatric treatment.

While advance directives are quite promising as tools for empowering consumers to more actively participate in their own treatment, there are legitimate concerns about these instruments as well. One of the thorniest issues concerns determinations of legal capacity or competence. Questions about capacity arise at two different points in the process. First, declarants must be competent at the time they draft advance directives for these documents to be valid. Second, an advance directive may be used for healthcare or psychiatric decisions only when the declarant is not competent to make these decisions him/herself.

Most state statutes presume that people are competent at the time they draft advance directives. These laws generally require the directive to be signed by two adult witnesses who attest to the person’s capacity at the time the instrument is drafted. More difficult questions arise over determining capacity at the time advance directives are used for healthcare decisions. In some states, a judge must make capacity determinations. In other states, such as Oregon, the law specifies that capacity determinations may be made either by a judge or by two physicians. The latter approach would appear to be preferable. Presumably, declarants have some say in choosing which option to exercise in states that authorize both forms of determining capacity.

Another controversial issue concerns the potential use of psychiatric advance directives to refuse all treatment. Thomas Szasz, a leading anti-psychiatry proponent, was one of the first to advocate for the use of “psychiatric living wills” as a mechanism for refusing psychiatric treatment. All of the state laws authorizing psychiatric advance directives except Maine specify that declarants may use these directives to consent or refuse psychiatric treatment. Maine’s law authorizes the use of advance directives specifically to indicate treatment preferences. It is silent on whether these directives can be used to refuse treatment.

Since advance directives for mental health decision making are quite new, courts have not ruled conclusively on whether and under what circumstances directives refusing all psychiatric treatment can be overridden. However, in view of general legal precedents on treatment refusals, it is likely that courts will find that advance directives refusing all treatment can be overridden under specific circumstances, namely when declarants are determined to be dangerous to self or others.

Another unresolved question concerns revocation of advance directives. Clearly, an individual may revoke an advance directive when competent. A more difficult question arises when an individual tries to revoke his/her advance directive while actively symptomatic and in need of treatment. For example, an individual may write an advance directive specifying preferred medications and assigning health care power of attorney to a family member to act in her behalf should she lose capacity to make her own treatment decisions. Subsequently, during a relapse, she may seek to revoke her advance directive and refuse all treatment. A lengthy court proceeding could ensue to determine capacity and whether her treatment refusal should be overridden. This negates an important objective of advance directives, which is to avoid court proceedings of this nature.

It has been suggested that the insertion of a so-called “Ulysses clause” in an advance directive could effectively avoid this dilemma. This name originated from the mythical Greek hero, Ulysses, who knew that the lure of the beautiful Sirens was so powerful that he would be compelled to sail his ship towards the rocks they were sitting on, thereby destroying it. To prevent this, he ordered his subordinates to bind him to the mast of the ship and to keep the ship sailing straight, no matter how strongly he argued to the contrary. A Ulysses clause in an advance directive instructs treatment providers about specific treatment preferences, and explains that any statements made refusing treatment during periods of incapacity should be ignored.

Notwithstanding all of these complicating factors, the situations described in the vignettes above could be resolved with an appropriate advance directive. In the first vignette, an advance directive would enable Jane to communicate her preferences and concerns about specific medications. It would also enable her to identify a substitute decision maker if she becomes incapacitated and unable to act in her own behalf. In the second vignette, since John, when stable, understands his need for treatment, he could similarly draft an advance directive when competent expressing his treatment preferences and assigning health care power of attorney to one or both of his parents.

The use of advance directives for psychiatric decision making is in its infancy. Clearly, there are more unresolved questions than answers about these instruments. While advance directives have many proponents, there are also some who argue that they will be used as vehicles for avoiding psychiatric treatment altogether. Ongoing research projects and pending court decisions should provide more comprehensive information in the future. In the meantime, advance directives should be strongly considered as a way to empower consumers to take a more active role in their own treatment, and as a way to avoid damaging, divisive conflicts over treatment and medication issues.

——————————————————————————–
RON S. HONBERG is Director of Legal Affairs for the National Alliance for the Mentally Ill (NAMI) and earned his Juris Doctor degree from the University of Maryland School of Law in 1990. A member of the Maryland Bar, he also holds a Masters Degree in Counseling from the University of Maryland and is a former president of the Maryland Rehabilitation

Posted in News & updates | Leave a comment